close :

:

Forgotten your password?
 
Pharma Industry News
Printable Version   Email to a friend

Kentucky Pharmacists Event Urging Senate Minority Leader McConnell to Fix Flawed Medicaid Drug Reimbursement Rule

FRANKFORT, Ky., December 05, 2007 /PRNewswire-USNewswire/ -- Kentucky pharmacist press conference to discuss new Medicaid generic prescription drug reimbursement rule and the need for Sen. Mitch McConnell (R-Ky.) to use his power to make sure the legislative fix is considered before Congress adjourns for the year. The rule, scheduled to be fully implemented in early 2008, will grossly underpay pharmacists and puts patient access at risk.

, Executive Director of the Kentucky Pharmacists Association

, RPh, Owner of Capital Pharmacy and Medical Equipment in Frankfort

, RPh, Co-Owner of Wayne's Pharmacy in Frankfort

December 6, 2007, at 10:00 a.m.

Capital Pharmacy and Medical Equipment

662 East Main Street

Frankfort, KY

502-223-2827

The Centers for Medicare and Medicaid Services published the Medicaid reimbursement rule on July 17, and the implementation process will be completed in early 2008. At that time, community pharmacies will be faced with a burden that could not only cause difficulty in participating in the Medicaid program, but sustainability in the business community. These challenges will be due to low reimbursement rates based on an inaccurate Average Manufacturer Price (AMP) formula. According to a Government Accountability Office report, on average, pharmacies will be paid 36 percent below their acquisition costs for the generic prescriptions of Medicaid patients.

Sen. McConnell can help move the legislative fix S.1951, the , through the Senate before it is too late. The bill contains measures that achieve fairness with the reimbursement system and preserving patient access to prescription drugs by:

-- Removing discounted mail order and pharmacy benefit manager prices that are unavailable to community pharmacies and unfairly lower than the overall AMP formula

-- Requiring Medicaid payment be calculated using the weighted average of the Medicaid generic drugs based on their actual utilization

-- Restoring the practice of using three available generic products for the calculation; increases the maximum allowable reimbursement from 250 percent of the AMP to 300 percent

-- Encouraging more inexpensive generic drug usage by requiring prior authorization of brand name drugs.

CONTACT: Chip Riddleberger of National Community Pharmacists Association,+1-410-725-6024, chip.riddleberger@ncpanet.org

Web site: http://www.ncpanet.org//

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


Most Popular Internet Searches
Latest FDA Drug Alerts
July 24, 2008
Audience: Infectious disease and medical genetics healthcare professionals[Posted 07/24/2008] FDA informed healthcare...
July 17, 2008
Audience: Radiological healthcare professionals, cardiologists, hospital risk managers [Posted 07/17/2008] FDA is updating...
July 16, 2008
Audience: Radiologists, surgeons, hospital risk managers, other healthcare professionals [Posted 07/16/2008] FDA informed...
July 16, 2008
Audience: Pharmacists, hospital risk managers, other healthcare professionals[Posted 07/16/2008] Roxane Laboratories, Inc....
More...
Latest Drug Information Updates

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

Trivaris
Trivaris (triamcinolone acetonide) is a glucocorticoid corticosteroid delivered via intravitreal injection for the treatment of sympathetic ophthalmia, temporal arteritis, uveitis, and ocular inflammatory conditions unresponsive to topical corticosteroids.

Entereg
Entereg (alvimopan) is a peripherally-acting mu opioid receptor antagonist used to help patients regain gastrointestinal (GI) function earlier following bowel resection surgery.

OraVerse
OraVerse is a dental anesthetic reversal agent that accelerates the return to normal sensation and function following dental procedures.

Aplenzin
Aplenzin is a once-daily formulation of bupropion hydrobromide indicated for the treatment of depression in adults.

Cimzia
Cimzia is a PEGylated anti-TNF (tumor necrosis factor) biologic therapy for the treatment of moderately to severely active Crohn’s disease in adults.

Relistor
subcutaneous injection for the treatment of opioid-induced constipation

Treximet
Treximet is the first and only migraine product designed to target multiple mechanisms of migraine by combining a triptan, a class of migraine-specific medicines, and an anti-inflammatory pain reliever in a single tablet.

Patanase
Patanase (olopatadine) is an antihistamine nasal spray for the treatment of symptoms of seasonal allergic rhinitis in adults and adolescents twelve years of age and older.

Lexiscan
Lexiscan (regadenoson) is an A2A adenosine receptor agonist indicated for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging (MPI), a test that detects and characterizes coronary artery disease, in patients unable to undergo adequate exercise stress.

More...